InfuSystem Stock Forecast, Price & News

+0.19 (+1.00 %)
(As of 06/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume42,825 shs
Average Volume97,380 shs
Market Capitalization$394.23 million
P/E Ratio22.66
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive INFU News and Ratings via Email

Sign-up to receive the latest news and ratings for InfuSystem and its competitors with MarketBeat's FREE daily newsletter.

InfuSystem logo

About InfuSystem

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates through two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment (DME) Services. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.85 out of 5 stars

Medical Sector

176th out of 2,102 stocks

Surgical & Medical Instruments Industry

18th out of 174 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

InfuSystem (NYSEAMERICAN:INFU) Frequently Asked Questions

Is InfuSystem a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InfuSystem in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" InfuSystem stock.
View analyst ratings for InfuSystem
or view top-rated stocks.

What stocks does MarketBeat like better than InfuSystem?

Wall Street analysts have given InfuSystem a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but InfuSystem wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is InfuSystem's next earnings date?

InfuSystem is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for InfuSystem

How were InfuSystem's earnings last quarter?

InfuSystem Holdings Inc. (NYSEAMERICAN:INFU) announced its quarterly earnings results on Thursday, May, 6th. The medical instruments supplier reported $0.03 EPS for the quarter, missing the Zacks' consensus estimate of $0.04 by $0.01. The medical instruments supplier had revenue of $24.46 million for the quarter, compared to analysts' expectations of $24.50 million. InfuSystem had a trailing twelve-month return on equity of 52.87% and a net margin of 18.36%.
View InfuSystem's earnings history

What guidance has InfuSystem issued on next quarter's earnings?

InfuSystem issued an update on its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $107 million-$110 million, compared to the consensus revenue estimate of $108.97 million.

What price target have analysts set for INFU?

3 brokers have issued 12-month price objectives for InfuSystem's stock. Their forecasts range from $26.00 to $28.00. On average, they expect InfuSystem's share price to reach $27.00 in the next year. This suggests a possible upside of 40.2% from the stock's current price.
View analysts' price targets for InfuSystem
or view top-rated stocks among Wall Street analysts.

Who are InfuSystem's key executives?

InfuSystem's management team includes the following people:
  • Mr. Richard A. DiIorio, CEO & Director (Age 46, Pay $1.06M)
  • Ms. Carrie Lachance B.S.N., R.N., Pres, COO & Director (Age 44, Pay $468.25k)
  • Mr. Barry G. Steele, Exec. VP & CFO (Age 50, Pay $475.12k)
  • Ms. Jeannine Lombardi Sheehan, Exec. VP & Chief Admin. Officer (Age 47)
  • Mr. Thomas Mark Ruiz, Exec. VP & Chief Commercial Officer (Age 63)
  • Jeanie Latz, Corp. Sec.

Who are some of InfuSystem's key competitors?

What other stocks do shareholders of InfuSystem own?

What is InfuSystem's stock symbol?

InfuSystem trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "INFU."

Who are InfuSystem's major shareholders?

InfuSystem's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Minerva Advisors LLC (4.38%), BlackRock Inc. (3.99%), Russell Investments Group Ltd. (3.26%), Renaissance Technologies LLC (2.63%), Punch & Associates Investment Management Inc. (2.17%) and Kennedy Capital Management Inc. (1.38%). Company insiders that own InfuSystem stock include Awm Investment Company, Inc, Barry G Steele, Blueline Capital Partners Ii,, Carrie Lachance, Christopher R Sansone, Gregg Owen Lehman, Jeannine Sheehan, Meridian Ohc Partners, Lp, Paul Andrew Gendron, Richard Dilorio, Scott Shuda and Thomas Mark Ruiz.
View institutional ownership trends for InfuSystem

Which institutional investors are selling InfuSystem stock?

INFU stock was sold by a variety of institutional investors in the last quarter, including Minerva Advisors LLC, Wedge Capital Management L L P NC, EAM Investors LLC, Renaissance Technologies LLC, Friess Associates LLC, EAM Global Investors LLC, Northern Trust Corp, and Millennium Management LLC. Company insiders that have sold InfuSystem company stock in the last year include Blueline Capital Partners Ii,, Gregg Owen Lehman, Meridian Ohc Partners, Lp, Richard Dilorio, and Thomas Mark Ruiz.
View insider buying and selling activity for InfuSystem
or view top insider-selling stocks.

Which institutional investors are buying InfuSystem stock?

INFU stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, Goldman Sachs Group Inc., Calamos Advisors LLC, Kennedy Capital Management Inc., Acuitas Investments LLC, Sowell Financial Services LLC, Dimensional Fund Advisors LP, and Geode Capital Management LLC. Company insiders that have bought InfuSystem stock in the last two years include Awm Investment Company, Inc, Barry G Steele, Carrie Lachance, Christopher R Sansone, Jeannine Sheehan, Paul Andrew Gendron, Richard Dilorio, and Scott Shuda.
View insider buying and selling activity for InfuSystem
or or view top insider-buying stocks.

How do I buy shares of InfuSystem?

Shares of INFU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InfuSystem's stock price today?

One share of INFU stock can currently be purchased for approximately $19.26.

How much money does InfuSystem make?

InfuSystem has a market capitalization of $394.23 million and generates $97.39 million in revenue each year. The medical instruments supplier earns $17.33 million in net income (profit) each year or $0.80 on an earnings per share basis.

How many employees does InfuSystem have?

InfuSystem employs 282 workers across the globe.

What is InfuSystem's official website?

The official website for InfuSystem is ir.infusystem.com.

Where are InfuSystem's headquarters?

InfuSystem is headquartered at 31700 Research Park Dr, MADISON HEIGHTS, MI 48071-4627, United States.

How can I contact InfuSystem?

InfuSystem's mailing address is 31700 Research Park Dr, MADISON HEIGHTS, MI 48071-4627, United States. The medical instruments supplier can be reached via phone at +1-248-2911210.

This page was last updated on 6/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.